High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study

REFERENCES

1. 1.↵
   1. Avina-Zubieta JA,
   2. Choi HK,
   3. Sadatsafavi M,
   4. Etminan M,
   5. Esdaile JM,
   6. Lacaille D

   . Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. Arthritis Rheum 2008;59:1690–7.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Westlake SL,
   2. Colebatch AN,
   3. Baird J,
   4. Curzen N,
   5. Kiely P,
   6. Quinn M,
   7. et al.

   Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: A systematic literature review. Rheumatology 2011;50:518–31.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Van Sijl AM,
   2. Peters MJ,
   3. Knol DL,
   4. de Vet RH,
   5. Sattar N,
   6. Dijkmans BA,
   7. et al.

   The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: A meta-analysis. Semin Arthritis Rheum 2011;41:393–400.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Di Angelantonio E,
   2. Sarwar N,
   3. Perry P,
   4. Kaptoge S,
   5. Ray KK,
   6. Thompson A,
   7. et al.

   Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993–2000.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. van Eijk IC,
   2. de Vries MK,
   3. Levels JH,
   4. Peters MJ,
   5. Huizer EE,
   6. Dijkmans BA,
   7. et al.

   Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: A prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009;60:1324–30.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Levels JH,
   2. Bleijlevens B,
   3. Rezaee F,
   4. Aerts JM,
   5. Meijers JC

   . SELDI-TOF mass spectrometry of high-density lipoprotein. Proteome Sci 2007;5:15.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Levels JH,
   2. Geurts P,
   3. Karlsson H,
   4. Maree R,
   5. Ljunggren S,
   6. Fornander L,
   7. et al.

   High-density lipoprotein proteome dynamics in human endotoxemia. Proteome Sci 2011;9:34.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Watanabe J,
   2. Charles-Schoeman C,
   3. Milao Y,
   4. Elashoff D,
   5. Lee YY,
   6. Katselis G,
   7. et al.

   Proteomic profiling following immunoaffinity capture of HDL: Association of acute phase proteins and complement factors with pro-inflammatory HDL in rheumatoid arthritis. Arthritis Rheum 2012;64:1828–37.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Heinecke JW

   . The HDL proteome: A marker — and perhaps mediator — of coronary artery disease. J Lipid Res 2009;50 Suppl:S167–71.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Rohrer L,
    2. Hersberger M,
    3. von Eckardstein A

    . High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 2004;15:269–78.

    OpenUrlCrossRefPubMed